# Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

> **NCT02958865** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 319 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** PF-06651600 or Placebo
- **DRUG:** PF-06700841 or Placebo
- **DRUG:** PF-06700841
- **DRUG:** PF-06651600

## Key facts

- **NCT ID:** NCT02958865
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-03
- **Primary completion:** 2021-05-10
- **Final completion:** 2021-05-10
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02958865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02958865, "Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02958865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*